MorphoSys AG (MPSYY.PK) reported first-quarter profit before interest and taxes, or EBIT, from continued operations of 2.5 million euros, compared to a loss of 0.7 million euros last year. Profit from continuing operations was 1.9 million euros or 0.08 euros per share, compared to a loss of 0.3 million euros or 0.01 euros per share last year.
Consolidated net profit was 7.9 million euros or 0.33 euros per share, compared to a loss of 0.5 million euros or 0.02 euros per share prior year.
Group revenues from continuing operations increased to 16.9 million euros from 11.7 million euros last year. The revenue growth resulted predominantly from a license payment from Bio-Rad for a non-exclusive license for HuCAL in research and diagnostic applications in connection with their purchase of MorphoSys's research and diagnostic segment AbD Serotec.
MorphoSys re-confirmed its guidance for 2013. Without taking into account a successful out-licensing of one of its proprietary compounds, MorphoSys anticipates total Group revenues of 48 million euros to 52 million euros and anticipates an EBIT in the range of loss of 18 million euros to loss of 22 million euros in 2013.
For comments and feedback: editorial@rttnews.com